A questionnaire for men with prostate cancer that evaluates comorbidities may help in clinical decision-making about treatment by estimating their likelihood of dying from other conditions, researchers found.
A study of almost 3,000 responses to the Total Illness Burden Index for Prostate Cancer (TIBI-CaP) questionnaire found that those men who scored highest were 10 times more likely to die of causes other than prostate cancer compared with men with the lowest scores (HR 10.3, 95% CI 5.4 to 19.5), according to Timothy Daskivich, MD, of the University of California, Los Angeles, and colleagues.
These results suggest that the presence and severity of comorbidities should be a key consideration in clinical decision-making for prostate cancer because of the indolence of many early stage cases, Daskivich and co-authors wrote in a research letter published in the August 9/23 Archives of Internal Medicine.
Continue Reading
No comments:
Post a Comment